All In Biotech

Drug Trial Radar · NCT07831577

Efficacy and Safety of GNSC-001 Intra-articular Injection for Knee Osteoarthritis

A Randomized, Double-blind, Placebo-controlled, Phase 2/3, Study to Evaluate the Efficacy and Safety of an Intraarticular Injection of GNSC-001 in Participants With Osteoarthritis of the Knee

Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Jul 2027

Primary completion

Oct 2029

Study completion Oct 2030

Sponsor

Lead sponsor
Genascence CorporationIndustry
Sponsor type
Industry
First posted
Sep 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if GNSC-001 works to treat knee osteoarthritis in adults. It will also learn about the safety of GNSC-001. The main questions it aims to answer are: 1. Does GNSC-001 lower daily knee joint pain and improve function in participants? 2. What medical problems do participants have when taking GNSC-001? Researchers will compare GNSC-001 to a placebo (a look-alike substance that contains no drug) to see if GNSC-001 works to treat knee osteoarthritis. Participants will: 1. Receive a single injection of immune-modulation, and GNSC-001 or a placebo, in their knee 2. Take an oral immune-modulating pill every day for the first 22 days 3. Visit the clinic at least 9 times over 2 years for checkups and tests 4. Keep a diary of their symptoms and the number of times they use a rescue medication

Conditions

  • Knee Arthritis Osteoarthritis
  • Knee Arthritis, Osteoarthritis
  • Knee Arthritis
  • Knee Arthritis Disease
  • Osteo Arthritis of the Knee
  • Osteoarthritic Knee Pain
  • Osteoarthritis (OA) of the Knee
  • Osteo Arthritis Knee
  • Pain (Knee)

Interventions

  • Gene Therapy GNSC-001Drug

    Single intra-articular injection into target knee

  • PlaceboDrug

    Single intra-articular injection into target knee

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in OA pain as assessed by the Weekly Average of Daily Pain (WADP) Numeric Rating Scale (NRS) at Week 52Time frame: Baseline and Week 52
  2. Change from baseline in the function subscale of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) at Week 52Time frame: Baseline and Week 52
  3. Incidence and severity of treatment emergent adverse events (TEAEs), events of clinical interest (ECIs), and serious adverse events (SAEs)Time frame: From enrollment to the end of study at 104 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.